CN103890246A - 可溶性多肽 - Google Patents

可溶性多肽 Download PDF

Info

Publication number
CN103890246A
CN103890246A CN201280047892.XA CN201280047892A CN103890246A CN 103890246 A CN103890246 A CN 103890246A CN 201280047892 A CN201280047892 A CN 201280047892A CN 103890246 A CN103890246 A CN 103890246A
Authority
CN
China
Prior art keywords
seq
polypeptide
iglv3
iglv1
scaffold
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280047892.XA
Other languages
English (en)
Chinese (zh)
Inventor
马修·大卫·贝亚斯利
基思·菲利普·尼文
本·罗斯·基费尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affinity Biosciences Pty Ltd
Original Assignee
Affinity Biosciences Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2011903298A external-priority patent/AU2011903298A0/en
Application filed by Affinity Biosciences Pty Ltd filed Critical Affinity Biosciences Pty Ltd
Publication of CN103890246A publication Critical patent/CN103890246A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C07K2317/82—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies functional in the cytoplasm, the inner aspect of the cell membrane, the nucleus or the mitochondria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201280047892.XA 2011-08-18 2012-08-17 可溶性多肽 Pending CN103890246A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2011903298 2011-08-18
AU2011903298A AU2011903298A0 (en) 2011-08-18 Soluble polypeptides
PCT/AU2012/000970 WO2013023251A1 (en) 2011-08-18 2012-08-17 Soluble polypeptides

Publications (1)

Publication Number Publication Date
CN103890246A true CN103890246A (zh) 2014-06-25

Family

ID=47714621

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280047892.XA Pending CN103890246A (zh) 2011-08-18 2012-08-17 可溶性多肽

Country Status (8)

Country Link
US (1) US10087261B2 (enExample)
EP (1) EP2744931B1 (enExample)
JP (1) JP6244301B2 (enExample)
CN (1) CN103890246A (enExample)
CA (1) CA2845391C (enExample)
DK (1) DK2744931T3 (enExample)
ES (1) ES2682254T3 (enExample)
WO (1) WO2013023251A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2744931T3 (en) 2011-08-18 2018-08-06 Affinity Biosciences Pty Ltd SOLUBLE POLYPEPTIDES
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
HRP20191865T1 (hr) 2013-01-14 2020-01-10 Xencor, Inc. Novi heterodimerni proteini
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
CA2901385A1 (en) * 2013-02-20 2014-08-28 Affinity Biosciences Pty Ltd Cytoplasmic expression of fab proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
EP3587448B1 (en) * 2013-03-15 2021-05-19 Xencor, Inc. Heterodimeric proteins
CA2911514A1 (en) 2013-05-06 2014-11-13 Scholar Rock, Inc. Compositions and methods for growth factor modulation
EP3954713A3 (en) 2014-03-28 2022-03-30 Xencor, Inc. Bispecific antibodies that bind to cd38 and cd3
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
IL278574B2 (en) 2014-11-12 2024-11-01 Seagen Inc Glycan-interacting compounds and methods of use
CN116333153A (zh) 2014-11-26 2023-06-27 森科股份有限公司 结合cd3和肿瘤抗原的异二聚体抗体
EP3223907A2 (en) 2014-11-26 2017-10-04 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd38
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
PE20240142A1 (es) 2015-08-19 2024-02-01 Pfizer Anticuerpos inhibidores via del factor tisular y usos de los mismos
WO2017083582A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
KR20180085800A (ko) 2015-12-07 2018-07-27 젠코어 인코포레이티드 Cd3 및 psma에 결합하는 이종이합체성 항체
IL263542B2 (en) 2016-06-14 2024-10-01 Xencor Inc Bispecific antibodies inhibit immunological checkpoint
KR20190020341A (ko) 2016-06-28 2019-02-28 젠코어 인코포레이티드 소마토스타틴 수용체 2에 결합하는 이종이량체 항체
WO2018094143A1 (en) 2016-11-17 2018-05-24 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
KR20240044544A (ko) 2017-03-03 2024-04-04 씨젠 인크. 글리칸-상호작용 화합물 및 사용 방법
AU2018366199A1 (en) 2017-11-08 2020-05-28 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
AU2018383600B2 (en) 2017-12-11 2025-10-02 Abalone Bio, Inc. Yeast display of proteins in the periplasmic space
CN112469477A (zh) 2018-04-04 2021-03-09 Xencor股份有限公司 与成纤维细胞活化蛋白结合的异源二聚体抗体
AU2020232605A1 (en) 2019-03-01 2021-10-21 Xencor, Inc. Heterodimeric antibodies that bind ENPP3 and CD3
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
KR102607909B1 (ko) 2020-08-19 2023-12-01 젠코어 인코포레이티드 항-cd28 조성물
JP2024511319A (ja) 2021-03-09 2024-03-13 ゼンコア インコーポレイテッド Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体
JP2024509274A (ja) 2021-03-10 2024-02-29 ゼンコア インコーポレイテッド Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004003144A2 (en) * 2002-07-01 2004-01-08 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
WO2010028791A1 (en) * 2008-09-10 2010-03-18 Philochem Ag Display library for antibody selection
WO2010136598A1 (en) * 2009-05-29 2010-12-02 Morphosys Ag A collection and methods for its use
US20110118149A1 (en) * 2009-05-20 2011-05-19 Nicolas Fischer Synthetic Polypeptide Libraries and Methods for Generating Naturally Diversified Polypeptide Variants
WO2011075761A1 (en) * 2009-12-23 2011-06-30 Affinity Biosciences Pty Ltd Protein display

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4631190A (en) 1981-06-26 1986-12-23 Shen Wei C Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
FI101678B1 (fi) 1990-12-31 1998-08-14 Akzo Nv Happolabiileja kytkentämolekyylejä
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
US5556623A (en) 1993-03-30 1996-09-17 Eli Lilly And Company Antibody-drug conjugates
US20060228364A1 (en) 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
IT1307309B1 (it) 1999-12-30 2001-10-30 Enea Ente Nuove Tec Peptidi stabilizzanti, polipeptidi ed anticorpi che li comprendono.
DE60144063D1 (de) * 2000-12-18 2011-03-31 Dyax Corp Gerichtete bibliotheken die genetisch verpackt sind
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
CN103739706B (zh) 2002-05-22 2015-11-18 艾斯巴技术-诺华有限责任公司 在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法
KR20120133403A (ko) 2004-06-01 2012-12-10 도만티스 리미티드 증강된 혈청 반감기를 가지는 이특이성 융합 항체
EP2356270B1 (en) * 2008-11-07 2016-08-24 Fabrus Llc Combinatorial antibody libraries and uses thereof
CN102459591B (zh) 2009-05-20 2015-05-13 诺维莫尼公司 合成性的多肽文库以及用于建立具有天然多样性的多肽变体的方法
FR2945961B1 (fr) 2009-05-29 2012-07-13 Air Liquide Epuration d'un gaz contenant des oxydes d'azote
JP5195798B2 (ja) * 2010-03-23 2013-05-15 豊田合成株式会社 半導体発光素子の製造方法
ES2609313T3 (es) 2011-06-29 2017-04-19 Affinity Biosciences Pty Ltd Método de expresión de proteínas
DK2744931T3 (en) 2011-08-18 2018-08-06 Affinity Biosciences Pty Ltd SOLUBLE POLYPEPTIDES
CA2901385A1 (en) 2013-02-20 2014-08-28 Affinity Biosciences Pty Ltd Cytoplasmic expression of fab proteins
US9705121B2 (en) 2014-08-18 2017-07-11 Johnson Controls Technology Company Lead frame for a battery module

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004003144A2 (en) * 2002-07-01 2004-01-08 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
WO2010028791A1 (en) * 2008-09-10 2010-03-18 Philochem Ag Display library for antibody selection
US20110118149A1 (en) * 2009-05-20 2011-05-19 Nicolas Fischer Synthetic Polypeptide Libraries and Methods for Generating Naturally Diversified Polypeptide Variants
WO2010136598A1 (en) * 2009-05-29 2010-12-02 Morphosys Ag A collection and methods for its use
CN102449149A (zh) * 2009-05-29 2012-05-09 莫佛塞斯公司 集合及其使用方法
WO2011075761A1 (en) * 2009-12-23 2011-06-30 Affinity Biosciences Pty Ltd Protein display

Also Published As

Publication number Publication date
US10087261B2 (en) 2018-10-02
US20140234313A1 (en) 2014-08-21
EP2744931A4 (en) 2015-01-21
AU2012297570A1 (en) 2013-05-02
EP2744931A1 (en) 2014-06-25
WO2013023251A1 (en) 2013-02-21
JP2014527408A (ja) 2014-10-16
JP6244301B2 (ja) 2017-12-06
CA2845391A1 (en) 2013-02-21
EP2744931B1 (en) 2018-05-02
ES2682254T3 (es) 2018-09-19
CA2845391C (en) 2021-01-19
DK2744931T3 (en) 2018-08-06

Similar Documents

Publication Publication Date Title
US10087261B2 (en) Soluble polypeptides
CN107074943B (zh) I型干扰素受体抗体及其用途
US20110189183A1 (en) Antibodies against candida, collections thereof and methods of use
US20160145328A1 (en) Modified Variable Domain Molecules And Methods For Producing And Using Same
US20060280734A1 (en) Retargeting
CN114853888A (zh) 抗tslp纳米抗体及其应用
CN116390953A (zh) 靶向人密蛋白18.2的抗体及其用途
TW202523704A (zh) 雙特異性抗體及其製造方法
JP2006521088A (ja) 抗活性化ｒａｓ抗体
AU2006329208B2 (en) Methods for generating and screening fusion protein libraries and uses thereof
WO2023134767A1 (zh) 一种靶向IL-18Rβ的抗体及其应用
WO2024188341A1 (zh) 特异性结合Claudin18.2的抗体及其制法和应用
US20160002317A1 (en) Cytoplasmic Expression of Fab Proteins
AU2012297570B2 (en) Soluble polypeptides
TWI906795B (zh) 特異性結合Ｃｌａｕｄｉｎ １８.２的抗體及其製法和應用
CN120981244A (zh) Vhh抗体和其用途
WO2025167373A1 (zh) 一种抗cd33的单域抗体、抗cd123抗体、靶向cd33和cd123分子的多肽及其用途
CN118745224A (zh) Tslp鲨鱼单域抗体及其应用
CN120904338A (zh) 结合人免疫球蛋白e的鲨鱼源纳米抗体
WO2024111576A1 (ja) 抗ｇｐａ３３抗体及びその利用
CN121152800A (zh) 特异性结合Claudin18.2的抗体及其制法和应用
CN120826416A (zh) 抗间皮素双特异性抗体及其使用方法
CN120882746A (zh) 结合至nkg2a和pd-l1的药剂及其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20140625